Study aim: Evaluation of the effect of nebulized and endotracheal epinephrine in the treatment of Covid-19 pneumonia Design: A phase 2-3, placebo-controlled, paralleled, single-blind, randomized clinical trial, 84 patients Settings and conduct: This study will be conducted at the Shahid Mohammadi Hospital and Khalij e Fars Hospital, Hormozgan, Bandar Abbas. The study population is 84 patients with COVID-19 (42 patients in treatment group and 42 in placebo group). Participants/Inclusion and exclusion criteria: Inclusion criteria: Age between 18 and 80 years, Positive polymerase chain reaction (PCR) test for COVID-19, Hospitalized, and Signing informed consent and willingness of study participant to accept randomization to any assigned treatment. Exclusion criteria: Contraindications epinephrine including, hemorrhagic CVA, TIA, and acute MI, Heart rate > 100, History of allergy to epinephrine, Pregnancy, and breastfeeding. Intervention groups: Treatment group will receive the intratracheal epinephrine for intubated patients, and nebulizer form of epinephrine for non-intubated patients at a dose of 200 micrograms three times a day for five days, in addition to the standard treatment. Placebo group will receive distilled water for intubated patients and non-intubated patients at a same volume three times a day for five days, in addition to the standard treatment. Main outcome variables: Checking the clinical symptoms, O2 saturation, Evaluation of pulmonary imaging, Occurrence of adverse drug reactions